ADC TOXICITY ATLAS
Payloads & linkers
Linker

VA dipeptide (tesirine)

Cleavable

[H]OC([H])([H])c1c([H])c([H])c(N([H])C(=O)[C@@]([H])(N([H])C(=O)[C@@]([H])(N([H])C(=O)C([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])OC([H])([H])C([H])([H])N([H])C(=O)C([H])([H])C([H])([H])N2C(=O)C([H])=C([H])C2=O)C([H])(C([H])([H])[H])C([H])([H])[H])C([H])([H])[H])c([H])c1[H]
Physicochemistry

Properties

MW
867.991 Da
TPSA
247.85 Ų
xLogP
-0.2829
Formula
C41H65N5O15
Cleavage
Cleavable
Attachment
Site-specific (engineered Cys)
4 agents

ADCs built on this linker

Agent · target
Ocular
Hepatic
Neutrop.
Thrombo.
Anemia
GI
ILD
Neuro.
MEDI2228TNFRSF17
53.7
24.4
11.2
31.7
15
22.4
15.9
Camidanlumab tesirineIL2RA
0.9
31.6
16.2
20.5
24.8
27.4
3.4
6.8
Rovalpituzumab tesirineDLL3
0.5
13
9
22
11
24
1.9
Loncastuximab tesirineCD19
0
57
52
58
51
23
0%severity100%
0
Assessed · clear
true 0%
No data
never assessed